Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 206.62B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 12.74 |
| Forward PE | 10.80 |
| Dividend | 2.91 (3.49%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 2,247 |
| Average Volume | 4,411 |
| Open | 85.00 |
| Previous Close | 85.30 |
| Day's Range | 83.20 - 85.50 |
| 52-Week Range | 65.50 - 99.40 |
| Beta | 0.30 |
| RSI | 49.65 |
| Earnings Date | Feb 3, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm
The U.S. Food and Drug Administration granted conditional approval for a Merck Animal Health pour-on treatment for the prevention and treatment of New World Screwworm, with farmers able to receive dos...
Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump
The company is finding ways to overcome the headwinds it will encounter in the medium term.
1 Major Factor Behind the Healthcare Sector's Recent Surge
Eli Lilly's GLP-1 drug became the world's best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other companies are soaring on new drugs or the growth of existing ones.
BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research
TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a renewed two-year contract with Merck, known as MSD outside of the United...
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydu...
Noteworthy Monday Option Activity: ADBE, MRK, GLW
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Adobe Inc (Symbol: ADBE), where a total of 25,838 contracts have traded so far, representing app...
Company News for Dec 8, 2025
Companies in The News Are: WBD, NFLX, MRK, VSCO, NRG
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Telecom giant Verizon has the highest yield in the Dow at 6.8%. Energy Goliath Chevron currently offers a hefty 4.6% yield.
Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?
After a long hiatus, why are the bulls so willing to buy in now?
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (December 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Do These 3 Healthcare Stocks Need a Checkup?
Pfizer has a sizable 6.8% yield and is down nearly 60% from its 2021 highs. Bristol Myers Squibb has a 5% yield and is off its 2023 highs by nearly 40%.
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
Vaccine makers expressed concern on Friday's decision by a U.S. advisory panel to scrap its long-standing recommendation that all infants receive a hepatitis B vaccine at birth, a shift that public he...
Is This Pharmaceutical Giant a Buy After a Major Acquisition?
Merck's newest acquisition could help it launch a promising flu candidate. Several other ongoing developments are helping paint a bright post-Keytruda picture.
These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them?
New markets are opening up for Albemarle's lithium products. Recent 3M spinoff Solventum is finding its footing.
Merck Unit Gets FDA Conditional Approval For EXZOLT CATTLE-CA1 To Treat Key Cattle Parasites
(RTTNews) - Merck Animal Health, a division of Merck & Co., Inc.(MRK), announced that the U.S. Food and Drug Administration has granted conditional approval for EXZOLT CATTLE-CA1 (fluralaner topical s...
Jim Cramer checks up on pharmaceutical company Merck
'Mad Money' host Jim Cramer takes a closer look at recent market gains out of Merck.
After Hours Most Active for Dec 4, 2025 : AVPT, NVDA, CMCSA, INTC, KO, WMB, GM, DIS, MRK, AMZN, AAPL, BSX
The NASDAQ 100 After Hours Indicator is down -2.19 to 25,579.51. The total After hours volume is currently 122,958,176 shares traded.The following are the most active stocks for the after hours sessio...
Merck & Co Inc at Citi Global Healthcare Conference Transcript
Merck & Co Inc at Citi Global Healthcare Conference Transcript
Halozyme (HALO) Wins Injunction Against Merck in Germany
Halozyme (HALO) Wins Injunction Against Merck in Germany
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda
Munich court halts Merck's Keytruda subcutaneous launch in Germany over Halozyme patent dispute. Read more here.
German Court Issues Injunction Against Merck's (MRK) Keytruda SC
German Court Issues Injunction Against Merck's (MRK) Keytruda SC
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Pliant Therapeutics, Inc . (NASDAQ: PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline. PLRX stock is showing notable weakness. Check out ...
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline.
Merck (MRK) Gains FDA Conditional Approval for New Cattle Treatment
Merck (MRK) Gains FDA Conditional Approval for New Cattle Treatment
FDA Conditionally Approves Merck Animal Health's EXZOLT CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administr...